The role of colchicine in the treatment of covid-19 patients
Phase 2
- Conditions
- Covid-19.Pneumonia due to SARS-associated coronavirusJ12.81
- Registration Number
- IRCT20210913052467N1
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Proved Covid-19 diagnosis based on positive PCR test or clinical evidence and CT scan of the lung
Hospitalized in the intensive care unit
Satisfaction for the study
Exclusion Criteria
Pregnancy or breastfeeding
Liver failure
Patient dissatisfaction
Sensitivity to colchicine
Renal glomerular clearance less than 20
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Disease severity. Timepoint: At the beginning of the study and 10 days after the intervention. Method of measurement: APACHE Score II.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does colchicine target in SARS-CoV-2 infection and COVID-19 pneumonia?
How does colchicine compare to standard-of-care treatments for severe COVID-19 in ICU patients?
Which biomarkers could predict response to colchicine in SARS-CoV-2-induced J12.81 pneumonia?
What are the potential adverse events associated with colchicine use in ICU COVID-19 patients?
Are there combination therapies involving colchicine showing improved outcomes for SARS-CoV-2 treatment?